RxDoctor Payments Data

Eugene Tolomeo, MD

Neurology · Canandaigua, NYNPI 1245257013

Payments from drug & device makers

$122,706in general payments, 2019–2025

Across 1,893 payments — averaging $64.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Teva Pharmaceuticals USA, Inc.$29K
  • Pfizer$22K
  • F. Hoffmann-la Roche AG$17K
  • Sanofi$10K
  • Biohaven Pharmaceutical Holding Company Ltd.$9K
  • Genentech USA, Inc.$7K
  • plus $29K from 54 others

What the payments were for

  • Consulting fees$13,86311%
  • Speaking & faculty fees$62,73251%
  • Travel & lodging$13,85711%
  • Food & beverage$31,45026%
  • Education$8041%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Teva Pharmaceuticals USA, Inc.123$28,955
Pfizer109$21,656
F. Hoffmann-la Roche AG4$16,617
Sanofi45$10,420
Biohaven Pharmaceutical Holding Company Ltd.82$9,024
Genentech USA, Inc.152$7,126
AbbVie(2 entities)284$6,595
EMD Serono, Inc.106$3,238
Biogen113$2,155
Livanova USA, Inc.13$1,609
Sunovion Pharmaceuticals Inc.60$1,318
Amgen(2 entities)48$1,142
Lilly USA, LLC49$1,029
Lundbeck LLC59$889
Novartis55$815
Eisai Inc.19$722
Acadia Pharmaceuticals Inc69$721
Biohaven Pharmaceuticals, Inc.70$580
Amneal Pharmaceuticals LLC37$579
Supernus Pharmaceuticals, Inc.44$557
SK Life Science, Inc.20$521
Neurocrine Biosciences, Inc.44$472
Bristol Myers Squibb24$368
UCB, Inc.20$365
TG Therapeutics, Inc.9$293
Genentech, Inc.7$278
Jazz Pharmaceuticals Inc.8$277
MDD US Operations, LLC15$262
Acorda Therapeutics, Inc13$260
Avanir Pharmaceuticals, Inc.16$255
Johnson & Johnson(2 entities)18$255
Argenx US, Inc.8$255
Grifols USA, LLC15$237
AstraZeneca(2 entities)10$222
Kyowa Kirin, Inc.10$214
Alnylam Pharmaceuticals Inc.10$209
Silk Road Medical, Inc.1$194
Neurelis, Inc.6$188
Abbott8$180
Merz Pharmaceuticals, LLC7$179
Avadel CNS Pharmaceuticals, LLC14$159
Otsuka America Pharmaceutical, Inc.6$140
Ipsen Biopharmaceuticals, Inc7$126
Takeda Pharmaceuticals U.S.A., Inc.4$108
CSL Behring6$93
Tanabe Pharma America, Inc.6$90
Catalyst Pharmaceuticals, Inc.2$83
E.r. Squibb & Sons, L.L.C.4$80
Adamas Pharmaceuticals, Inc.6$80
Banner Life Sciences, LLC4$75
Upsher-smith Laboratories LLC2$67
Greenwich Biosciences, Inc.4$59
GE HealthCare4$59
Vertical Pharmaceuticals, LLC3$36
Mallinckrodt Hospital Products Inc.1$34
Vanda Pharmaceuticals Inc.1$29
Promius Pharma LLC2$27
Avion Pharmaceuticals2$26
Medtronic1$26
Impel Pharmaceuticals Inc.1$25

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$122,706 in reported general payments places this provider in the 85th percentile of 1,623 neurology providers in New York.

See all neurology providers in New York

Medicare billing

Part B allowed, 2024
$306,115
Medicare patients
243
Services billed
36,021

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov5017$280,990
Austedo XrDeutetrabenazine14$193,633
IngrezzaValbenazine Tosylate22$176,633
Nurtec OdtRimegepant Sulfate75$107,410
Gamunex-CImmune Globul G/Gly/Iga Avg 4628$104,529
BriviactBrivaracetam18$43,288
Ajovy AutoinjectorFremanezumab-Vfrm33$41,012
Emgality PenGalcanezumab-Gnlm41$38,005
Aimovig AutoinjectorErenumab-Aooe43$37,760
AptiomEslicarbazepine Acetate13$34,109
QuliptaAtogepant28$29,903
UbrelvyUbrogepant30$26,227
RytaryCarbidopa/Levodopa31$22,767
XcopriCenobamate17$17,530
Lamictal XrLamotrigine12$15,198

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Gammagard Liquid$108$280,99017 claims
Teva Pharmaceuticals USA, Inc.Austedo Xr$28,955$193,63314 claims
Neurocrine Biosciences, Inc.Ingrezza$472$176,63322 claims
PfizerNurtec Odt, Relpax$21,656$114,68986 claims
Grifols USA, LLCGamunex-C$237$104,52928 claims
AbbVieQulipta, Ubrelvy$6,595$56,13058 claims
UCB, Inc.Briviact$365$43,28818 claims
Sunovion Pharmaceuticals Inc.Aptiom$1,318$34,10913 claims
Amneal Pharmaceuticals LLCRytary$579$22,76731 claims
SK Life Science, Inc.Xcopri$521$17,53017 claims
Upsher-smith Laboratories LLCTopiramate$67$2,125180 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,623 neurology providers in New York.

Other neurology in Canandaigua

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →